Aspira Pathlab & Diagnostics
Aspira Pathlab & Diagnostics (ASPIRA) share price was ₹125.65 at the 28 Oct 2026 close; market capitalisation ₹129 Cr; sector Healthcare Services. The share price rose 95.3% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 17.5% year on year to ₹6.17 Cr and net profit was −₹0.04 Cr, against ₹0.47 Cr a year earlier (compared with Jun 2025). Promoters held 46.65% of Aspira Pathlab & Diagnostics in Sep 2026, up 0.07 percentage points from Jun 2026. Its Tapetide Score is 57/100 (Good) as of 28 Oct 2026.
Key Fundamentals
MicrocapHealthcare ServicesHealthcarePrice-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Healthcare Services › Healthcare Service Provider
| ₹1,905.90 | 58.93 | 31,990 Cr | 12.75 | 0.26% | 20.06% | 25.67% | 2,996 Cr | 545 Cr | |
| ₹1,437.80 | 78.87 | 14,809 Cr | 15.47 | 0.14% | 18.07% | 19.22% | 879 Cr | 187 Cr | |
| ₹549.85 | 56.51 | 11,403 Cr | 7.59 | 0.91% | 12.54% | 15.73% | 1,733 Cr | 203 Cr | |
| ₹516.00 | 46.57 | 8,213 Cr | 16.02 | 2.84% | 27.79% | 33.84% | 894 Cr | 176 Cr | |
| ₹630.30 | 150.43 | 6,338 Cr | 5.68 | 0.00% | 6.88% | 13.46% | 1,079 Cr | 85 Cr | |
| ₹319.05 | 46.37 | 1,662 Cr | 6.79 | 0.16% | 12.90% | 14.70% | 329 Cr | 35 Cr | |
| ₹494.80 | 16.23 | 1,605 Cr | 1.64 | 0.40% | 10.35% | 10.64% | 862 Cr | 98 Cr | |
| Aspira Pathlab & Diagnostics (this company) | — | — | 129 Cr | 17.72 | 0.00% | 16.62% | 15.71% | 23 Cr | -0 Cr |
| Median 8 companies | ₹549.85 | 56.51 | 7,276 Cr | 10.17 | 0.21% | 14.76% | 15.72% | 887 Cr | 137 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 91/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Debtor days have improved from 42.1 to 25.3 days.
- Promoter holding has increased by 28.2% over last quarter.
Weaknesses
5- Stock is trading at 16.0 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.59% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.0.53 Cr.
Technical Indicators
Oscillators
Bearish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 5.51% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.6 | 3.32 | 3.46 | 3.82 | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 | 8.09 | 5.12 | 6.52 | 6.17 |
| Expenses | 2.92 | 3.68 | 3.83 | 3.95 | 4.29 | 4.83 | 4.65 | 4.73 | 4.44 | 5.9 | 6.33 | 6.85 | 5.83 |
| Operating Profit | -0.32 | -0.36 | -0.37 | -0.13 | 0.35 | 1.35 | 0.76 | 1.05 | 0.81 | 2.19 | -1.21 | -0.33 | 0.34 |
| OPM % | -12.31% | -10.84% | -10.69% | -3.4% | 7.54% | 21.84% | 14.05% | 18.17% | 15.43% | 27.07% | -23.63% | -5.06% | 5.51% |
| Other Income | 0.1 | 0.14 | 0.1 | 0.08 | 0.09 | 0.08 | 0.09 | 0.13 | 0.11 | 0.14 | 0.13 | 0.14 | 0.12 |
| Interest | 0.1 | 0.1 | 0.09 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.1 | 0.1 | 0.1 | 0.09 |
| Depreciation | 0.39 | 0.39 | 0.38 | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 | 0.4 | 0.38 | 0.4 | 0.41 |
| PBT | -0.71 | -0.71 | -0.74 | -0.51 | -0.02 | 0.99 | 0.37 | 0.72 | 0.46 | 1.83 | -1.56 | -0.69 | -0.04 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.72 | -0.71 | -0.74 | -0.5 | -0.02 | 0.99 | 0.38 | 0.72 | 0.47 | 1.84 | -1.56 | -0.69 | -0.04 |
| EPS (₹) | -0.7 | -0.69 | -0.72 | -0.49 | -0.02 | 0.96 | 0.37 | 0.7 | 0.46 | 1.79 | -1.52 | -0.67 | -0.04 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0.76 | 4.36 | 7.64 | 8.42 | 15.21 | 19.54 | 14.46 | 13.2 | 22 | 24.98 | 25.9 |
| Expenses | 0.14 | 0.23 | 3.34 | 8.24 | 10.88 | 10.25 | 11.69 | 13.16 | 12.86 | 14.38 | 18.44 | 23.52 | 24.91 |
| Operating Profit | -0.14 | -0.23 | -2.58 | -3.88 | -3.24 | -1.83 | 3.52 | 6.38 | 1.6 | -1.18 | 3.56 | 1.46 | 0.99 |
| OPM % | — | — | -339.47% | -88.99% | -42.41% | -21.73% | 23.14% | 32.65% | 11.07% | -8.94% | 16.18% | 5.84% | 3.82% |
| Other Income | 0.21 | 0.32 | 0.31 | 0.22 | 0.25 | 0.29 | 0.2 | 0.09 | 0.32 | 0.42 | 0.36 | 0.52 | 0.53 |
| Interest | 0 | 0.05 | 0.26 | 0.8 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | 0.35 | 0.39 | 0.39 |
| Depreciation | 0 | 0 | 0.2 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.49 | 1.54 | 1.59 |
| PBT | 0.07 | 0.04 | -2.73 | -5.58 | -5.18 | -4.21 | 1.39 | 4.46 | -0.09 | -2.67 | 2.08 | 0.05 | -0.46 |
| Tax % | 57.14% | 25% | 0% | 0% | 0% | 0.71% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | 0.02 | 0.03 | -2.72 | -5.58 | -5.18 | -4.24 | 1.38 | 4.46 | -0.09 | -2.67 | 2.07 | 0.05 | -0.45 |
| EPS (₹) | 0.09 | 0.13 | -5.24 | -10.75 | -6.32 | -4.56 | 1.34 | 4.33 | -0.09 | -2.59 | 2.01 | 0.05 | -0.44 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.25 | 2.25 | 5.19 | 5.19 | 8.19 | 9.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 |
| Reserves | 1.36 | 1.39 | 0.72 | -4.86 | -7.93 | -10.42 | -6.91 | -2.43 | -2.47 | -5.08 | -3.01 | -2.99 |
| Borrowings | 0 | 2.62 | 7.29 | 11.36 | 12.52 | 13.8 | 7.01 | 8.85 | 8.24 | 7.71 | 8.13 | 8.25 |
| Other Liabilities | 0.21 | 0.03 | 1.66 | 0.84 | 2.02 | 1.67 | 1.39 | 1.42 | 1.28 | 1.79 | 2.11 | 2.95 |
| Total Liabilities | 3.82 | 6.29 | 14.86 | 12.53 | 14.8 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 18.5 |
| Fixed Assets | 0 | 0.04 | 7.79 | 7.91 | 8.9 | 8.7 | 7.75 | 9.57 | 8.01 | 6.79 | 6.53 | 7.2 |
| CWIP | 0 | 0 | 0.25 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.13 | 0 |
| Other Assets | 3.82 | 6.25 | 6.82 | 4.62 | 5.9 | 5.64 | 4.03 | 8.56 | 9.33 | 7.92 | 10.86 | 11.3 |
| Total Assets | 3.82 | 6.29 | 14.86 | 12.53 | 14.8 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 18.5 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | — | -0.37 | -1.29 | -4.81 | -3.39 | -1.87 | 5.67 | 2.03 | -0.01 | 1.05 | 1.88 | 1.45 |
| Investing | — | -0.02 | -10.14 | -0.77 | -1.97 | 0.24 | -0.09 | -0.51 | 0.16 | 0.14 | 0.07 | -0.8 |
| Financing | — | 2.64 | 8.91 | 6.52 | 3.35 | 1.27 | -2.17 | -1.35 | -0.94 | -0.95 | -0.99 | -1.14 |
| Net Cash Flow | — | 2.25 | -2.52 | 0.94 | -2 | -0.35 | 3.41 | 0.17 | -0.79 | 0.24 | 0.95 | -0.49 |
| Free Cash Flow | — | -0.41 | -8.41 | -5.81 | -3.9 | -1.92 | 5.37 | 1.42 | -0.15 | 0.79 | 1.71 | 0.75 |
| CFO/OP | — | 139 | 50 | 124 | 105 | 101 | 161 | 32 | -1 | -89 | 53 | 99 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | 43.22 | 29.3 | 38.22 | 26.01 | 40.8 | 83.87 | 59.07 | 61.94 | 38.99 | 25.28 |
| Inventory Days | — | — | 313 | 104 | 45.22 | 51.36 | 51.35 | 46.5 | 58.4 | 62.69 | 50.31 | 56.53 |
| Days Payable | — | — | 730 | 64.58 | 46.84 | 73.37 | 91.6 | 70.91 | 51.1 | 102 | 73 | 92.06 |
| Cash Conversion Cycle | — | — | -374 | 68.61 | 36.6 | 4 | 0.55 | 59.46 | 66.37 | 22.93 | 16.3 | -10.25 |
| Working Capital Days | — | — | -2,200 | -5.86 | -96.03 | -127 | 16.32 | 69.3 | 48.72 | 25.16 | 14.1 | -2.92 |
| ROCE % | — | 1.82% | -25.39% | -38.41% | -34.49% | -25.15% | 19.77% | 35.65% | 2.01% | -15.87% | 17.37% | 2.84% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aspira Pathlab & Diagnostics insights
59 extracted metrics + investor summaries across FY11–FY27.
Documents
Frequently Asked Questions about Aspira Pathlab & Diagnostics
What does Aspira Pathlab & Diagnostics Ltd do?
Where is Aspira Pathlab & Diagnostics Ltd (ASPIRA) listed?
Which sector does Aspira Pathlab & Diagnostics Ltd belong to?
What is the market capitalisation of Aspira Pathlab & Diagnostics Ltd?
What is the 52-week high and low of Aspira Pathlab & Diagnostics Ltd?
What is the Return on Equity (ROE) of Aspira Pathlab & Diagnostics Ltd?
Company Information
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540788.md for Aspira Pathlab & Diagnostics Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.